Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + Cetuximab
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Trial Timeline
Dec 13, 2022 → Sep 22, 2025
NCT ID
NCT05271604About Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + Cetuximab
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + Cetuximab is a phase 2 stage product being developed by BioAtla for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05271604. Target conditions include Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05271604 | Phase 2 | Completed |
Competing Products
20 competing products in Head and Neck Cancer